In addition, pharmacological inhibitors targeting HSP90β prevented the abnormal secretion of IL-1β from peripheral blood mononuclear cells (PBMCs) isolated from CAPS patients, except in cases of the most severe form of the disease. This evidence concerns the gene HSP90AB1 and cryopyrin-associated periodic syndrome.